Tag Archive for: Infectious disease

AlgiPharma collaboration with Cardiff University wins Medical Innovation Award

/in ,

A long standing collaboration between AlgiPharma and Professor David Thomas team at the School of Dentistry has been recognized this year by Cardiff University’s prestigious Medical Innovation Award. The award was presented by Dr. Rob Docherty on behalf of Cardiff University.

 

 

Click here for more information and link to the video

 

 

 

(Left to Right) Dr. Manon Pritchard (Cardiff), Dr. Phil Rye (AlgiPharma), Dr Rob Docherty (presenting the award), Prof. David Thomas (Cardiff), Dr. Katja Hill (Cardiff), Dr. Saira Khan (Cardiff), Mr Arne Dessen (AlgiPharma), Dr. Lydia Powell (Cardiff).

 

AlgiPharma awarded four year grant from Norwegian Research Council

/in ,

AlgiPharma has been awarded a new four year grant from the Norwegian Research Council for the project “Treatment of Chronic Infective Disease with Alginate Oligomer Based Formulations”. This study will focus on extended long term safety studies and formulation changes to further develop the AlgiPharma drug candidate OligoG for the treatment of cystic fibrosis.

For further information, please contact:
Arne Dessen, Chairman of Board; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

February 2015

AlgiPharma awarded four year grant from Norwegian Research Council

/in ,

AlgiPharma has been awarded a four year grant from the Norwegian Research Council for the project “Tailored OligoG in the treatment of chronic infectious biofilms”. This study involving an international consortium will investigate microbial sources of raw material for AlgiPharma’s alginate technology and determine optimal oligomer length associated with specific known OligoG antimicrobial properties.

For further information, please contact:
Arne Dessen, Chairman of Board; arne.dessen@algipharma.com
Philip D. Rye R&D Director; phil.rye@algipharma.com

July 2013

The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms

/in ,

Powell LC, Sowedan A, Khan S, Wright CJ, Hawkins K, Onsøyen E, Myrvold R, Hill KE, Thomas DW.
Biofouling. 2013 Apr;29(4):413-21. doi: 10.1080/08927014.2013.777954.

External link to Pubmed.gov

Abstract

The influence of a novel, safe antibiofilm therapy on the mechanical properties of Pseudomonas aeruginosa and Acinetobacter baumannii biofilms in vitro was characterized. A multiscale approach employing atomic force microscopy (AFM) and rheometry was used to quantify the mechanical disruption of the biofilms by a therapeutic polymer based on a low-molecular weight alginate oligosaccharide (OligoG). AFM demonstrated structural alterations in the biofilms exposed to OligoG, with significantly lower Young’s moduli than the untreated biofilms, (149 MPa vs 242 MPa; p < 0.05), a decreased resistance to hydrodynamic shear and an increased surface irregularity (Ra) in the untreated controls (35.2 nm ± 7.6 vs 12.1 nm ± 5.4; p < 0.05). Rheology demonstrated that increasing clinically relevant concentrations of OligoG (<10%) were associated with an increasing phase angle (δ) over a wide range of frequencies (0.1-10 Hz). These results highlight the utility of these techniques for the study of three-dimensional biofilms and for quantifying novel disruption therapies in vitro.

For further information, please contact:
Philip D. Rye R&D Director; phil.rye@algipharma.com

April 2013